Vaccine yielded encouraging long-term survival rates in certain patients with NSCLCApril 04, 2012
"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.
These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.
For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.
Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.
In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.
Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.
American Association for Cancer Research
Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles
TGen identifies key protein that helps prevent lung cancer tumors from being destroyed
Researchers at the Translational Genomics Research Institute (TGen) have discovered a protein, Mcl-1, that helps enable one of the most common and deadly types of cancer to survive radiation and drug treatments.
Afatinib: added benefit depends on mutation status
Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
'Weeding the garden' with radiation allows ALK+ lung cancer patients to continue crizotinib, increasing survival
A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
Study finds new genetic error in some lung cancers
A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion - a forced merger of two normally separate genes - that spurs the cells to divide rapidly, scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report in a new paper in the journal Nature Medicine.
Diabetes drug metformin with chemo and radiation may improve outcomes in lung cancer patients
Treating aggressive lung cancer with the diabetes drug metformin along with radiation and chemotherapy may slow tumor growth and recurrence, suggests new preliminary findings from researchers at the Perelman School of Medicine at the University of Pennsylvania being presented during an oral abstract session October 28 at the 15th World Conference on Lung Cancer.
Potential new drug for some patients with treatment-resistant lung cancer
The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors.
Promising results for new antibody drug in non-small cell lung cancer patients: Smokers respond well
New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.
MicroRNA-31 Might Predict Lung-Cancer Spread
Determining whether a patient's lung cancer has spread to nearby lymph nodes is critical for identifying the most effective therapy, but it usually requires surgery.
Patient-reported outcomes provide valuable insight regarding quality of life for patients with NSCLC
An analysis of quality of life (QOL) data of stage III lung cancer patients who received higher doses of radiation therapy (with chemotherapy) shows a significantly lower quality of life at 3 months after treatment compared to patients who received a standard dose of radiation (with chemotherapy).
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles